Select Publications

Atkins M et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005;11(10):3714-21. Abstract

Dutcher JP et al. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). Proc ASCO 2007;Abstract 5033.

Hudes G et al; Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-81. Abstract

Hudes G et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of firstline,
poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCO 2006;Abstract LBA4.

Motzer RJ et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20(1):289-96. Abstract

 

 

 

 

 

 

 

 

 

 

 

 

Home

Editor
Neil Love, MD

Interviews

Robert J Motzer, MD
- Select publications

Daniel J George, MD
- Select publications

Robert J Amato, DO
- Select publications

Janice P Dutcher, MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office